Polymorphic and amorphous salt forms of squalamine dilactate

Details Polymorphic and amorphous salt forms of squalamine dilactate Polymorphic and amorphous salt forms of squalamine dilactate

2011-07-19

2011-07-19

Padmanabhan, Sreeni (Department: 1627)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

C552S521000

Reexamination Certificate

active

07981876

ABSTRACT:
The invention relates to select squalamine salts, methods of their synthesis, their therapeutic use and their advantages relating to manufacturing, product stability and toxicity. More specifically, this application is directed to various forms of the dilactate salt of squalamine and their utility in inhibiting neovascularization and endothelial cell proliferation.

REFERENCES:
patent: 5716960 (1998-02-01), Kennedy et al.
patent: WO 03/080027 (2003-10-01), None
patent: WO2005/046589 (2003-11-01), None
Weis et. al., Tetrahedron Letters, 1999, Pergamon, vol. 40, pp. 4863-4864.
Greene et. al., Protective Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, 1999, pp. 173.
Vippagunta et. al., Advanced Drug Delivery Reviews, 2001, Elsevier Science, vol. 48, pp. 3-26.
Herbst et al., “A Phase I/IIA Trial of Continuous Five-Day Infusion of Sqaualamine Lactate (MSI-1256F) Plus Carboplatin and Paclitaxel in Patients with Advanced Non-Small Lung Cancer,” Clinical Cancer Research 9(11): 4108-4115 (2003); (XP002403212).
Bhargava et al., “A Phase I and Pharmacokinetic Study of Squalamine, a Novel Antiangiogenic Agent, in Patients with Advanced Cancers,” Clinical Cancer Research 7(12): 3912-3919 (2001); (XP002403213).
Li et al., “Determination of Degradation Products of Squalamine Lactate Using LC/MS,” Journal of Pharmaceutical and Biomedical Analysis 32(1): 85-96 (2003; (XP002403214).
Anonymous, “Squalamine Lactate (MSI-1256F),” [on-line] [retrieved on Oct. 16, 2006], Retrieved from the Internet: <URL: http://www.genaera.com/ARVO2004/images/slide02.gif>, pp. 1-2; (XP002403215).
Database ChemIDplus Advanced, “Squalamine Lactate,” [on-line] [retrieved on Sep. 10, 2004]. Retrieved from the Internet: <URL:http://chem.sis.nlm.nih.gov./chemidplus/jsp/common/ChemFull.jsp?MW=718.0469>, pp. 1-2; (XP002403216).
Brittain, “Polymorphism in Pharmaceutical Solids” (1999), Marcel Dekker, Inc., New York , pp. 235-238.
Examiner's Report for Australian Patent Application No. 2006239811, dated Feb. 9, 2011.
Official Communication for European Patent Application No. 06751251.7, dated Apr. 26, 2010.

Affiliated with

Also associated with

Rating

Polymorphic and amorphous salt forms of squalamine dilactate does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Polymorphic and amorphous salt forms of squalamine dilactate, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polymorphic and amorphous salt forms of squalamine dilactate will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2721767